Andelyn Biosciences and Evolyra Therapeutics Join Forces to Advance Gene Therapy Manufacturing for Rare Muscle Diseases

Collaboration Overview

In a significant development for the realm of gene therapy, Andelyn Biosciences has announced a strategic partnership with Evolyra Therapeutics. This collaboration aims to revolutionize treatment for Limb-Girdle Muscular Dystrophies (LGMDs), a group of rare genetic disorders that cause muscle weakness and degeneration. The partnership brings together innovative technologies and shared expertise to manufacture clinical-grade AAV gene therapies specifically targeting LGMD subtypes 2C and 2D.

About the Partners

Andelyn Biosciences is a well-regarded name in the cell and gene therapy landscape, operating as a Contract Development and Manufacturing Organization (CDMO). With over 20 years of industry experience, they possess a robust platform that supports various stages of gene therapy development. Their proprietary AAV Curator® Platform is designed to facilitate the manufacturing of high-quality adeno-associated virus (AAV) vectors, essential for effective gene therapy applications.

Evolyra Therapeutics, based in Richmond, Virginia, focuses on developing next-generation gene therapies for rare neuromuscular diseases. Their innovative approach involves the use of a muscle-targeting AAV vector known as AAVMYO2, which significantly improves muscle expression while reducing potential liver toxicity associated with earlier vectors. This collaboration leverages Andelyn's manufacturing capabilities to expedite Evolyra's IND-enabling studies and clinical trials.

The Need for Advanced LGMD Treatments

Limb-Girdle Muscular Dystrophies encompass a variety of rare genetic conditions that lead to progressive weakness, often beginning in the hip and shoulder muscles. Currently, the global market for LGMD treatments is estimated to exceed $100 billion, affecting over 580,000 individuals worldwide. Notably, Evolyra's focus on LGMDR3 and LGMDR5 represents a subset within this market, with the potential to serve approximately 20,000 patients globally.

Innovations in Gene Therapy

The partnership aims to apply Andelyn's expertise with their AAV Curator® Platform, ensuring a seamless transition through various phases of Evolyra's developmental process. With promising preclinical data showcasing complete protein expression and muscle restoration in animal models, the team is optimistic about the prospective outcomes of the clinical trials.

"Our mission aligns perfectly with Evolyra's ambition to bring transformative therapies to patients with rare diseases. This partnership underscores our commitment to accelerating access to innovative treatments," stated Matt Niloff, Chief Commercial Officer of Andelyn.

Evolyra's CEO, Dr. Nicholas Johnson, expressed gratitude for the support from Andelyn. He emphasized the importance of their platform in ensuring efficient progress and speedy delivery of these critical therapies to individuals living with LGMD.

Future Clinical Development

The collaborative efforts will propel Evolyra's project timeline forward, with plans for an IND submission in the latter half of 2026, followed by the commencement of Phase I/II clinical trials. Recently, Evolyra completed a successful seed funding round, acquiring $5 million to advance these promising therapies. They are now aiming for a significant $20 million in Series A funding to further develop their innovative treatment options.

In summary, the partnership between Andelyn Biosciences and Evolyra Therapeutics marks a crucial step forward in the fight against Limb-Girdle Muscular Dystrophies. With their combined expertise and commitment to patient-centered solutions, they are poised to make a meaningful impact on the lives of those affected by these challenging conditions.